[go: up one dir, main page]

CU24496B1 - Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk - Google Patents

Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk

Info

Publication number
CU24496B1
CU24496B1 CU2017000154A CU20170154A CU24496B1 CU 24496 B1 CU24496 B1 CU 24496B1 CU 2017000154 A CU2017000154 A CU 2017000154A CU 20170154 A CU20170154 A CU 20170154A CU 24496 B1 CU24496 B1 CU 24496B1
Authority
CU
Cuba
Prior art keywords
formula
cdk inhibitors
pirazole
amine derivatives
derivatives substituted
Prior art date
Application number
CU2017000154A
Other languages
English (en)
Other versions
CU20170154A7 (es
Inventor
Rajeev Goswami
Subhendu Mukherjee
Chetan Pandit
Ramulu Poddutoori
Susanta Samajdar
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of CU20170154A7 publication Critical patent/CU20170154A7/es
Publication of CU24496B1 publication Critical patent/CU24496B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona derivados heterocíclicos sustituidos de la fórmula (I),</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>que son terapéuticamente útiles, particularmente como inhibidores CDK transcripcionales selectivos incluyendo CDK7, CDK9, CDK12,CDK13, y CDK18, más concretamente CDK7 inhibidores transcripcionales. Estos compuestos son útiles en el tratamiento y prevención de enfermedades o trastornos asociados con las CDKs transcripcionales selectivas en un mamífero. La presente invención también proporciona preparación de los compuestos y formulaciones farmacéuticas que comprende al menos uno de los derivados heterocíclicos sustituidos de la fórmula (I) o una sal farmacéuticamente aceptable o un estereoisómero del mismo.</p>
CU2017000154A 2015-06-04 2016-06-03 Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk CU24496B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2803CH2015 2015-06-04
IN6214CH2015 2015-11-18
PCT/IB2016/053267 WO2016193939A1 (en) 2015-06-04 2016-06-03 Substituted heterocyclyl derivatives as cdk inhibitors

Publications (2)

Publication Number Publication Date
CU20170154A7 CU20170154A7 (es) 2018-07-05
CU24496B1 true CU24496B1 (es) 2021-01-12

Family

ID=57440798

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000154A CU24496B1 (es) 2015-06-04 2016-06-03 Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk

Country Status (21)

Country Link
US (3) US10689347B2 (es)
EP (2) EP4342540A3 (es)
JP (3) JP6750806B2 (es)
KR (1) KR102691467B1 (es)
CN (2) CN108024970B (es)
AU (3) AU2016272908B2 (es)
CA (1) CA2987552A1 (es)
CU (1) CU24496B1 (es)
DK (1) DK3302448T3 (es)
EA (1) EA037236B1 (es)
FI (1) FI3302448T3 (es)
HK (1) HK1255239A1 (es)
HR (1) HRP20240101T1 (es)
IL (2) IL255960B (es)
LT (1) LT3302448T (es)
MX (2) MX2017015521A (es)
MY (1) MY190459A (es)
NZ (1) NZ738825A (es)
PH (1) PH12017502179B1 (es)
SI (1) SI3302448T1 (es)
WO (1) WO2016193939A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
CA2978170C (en) * 2015-03-09 2024-02-27 Aurigene Discovery Technologies Limited Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
HRP20240101T1 (hr) * 2015-06-04 2024-03-29 Aurigene Oncology Limited Supstituirani heterociklil derivati kao cdk inhibitori
GB201617548D0 (en) 2016-10-17 2016-11-30 Linnane Pharma Ab Novel biological factor
TWI703149B (zh) 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
US11040945B2 (en) 2017-12-06 2021-06-22 Lin Bioscience Pty Ltd. Tubulin inhibitors
EP3746422A4 (en) * 2018-02-01 2021-06-09 The University Of Sydney ANTI-CANCER COMPOUNDS
PL3782986T3 (pl) * 2018-03-29 2024-12-02 Takeda Pharmaceutical Company Limited Związek heterocykliczny
CA3095987A1 (en) * 2018-04-04 2019-10-10 Aurigene Discovery Technologies Limited Substituted pyrazole derivatives as selective cdk12/13 inhibitors
EP3787629A4 (en) 2018-05-02 2022-01-05 Kinnate Biopharma Inc. INHIBITORS OF CYCLINE-DEPENDENT KINASES
CN110590747B (zh) * 2018-06-12 2022-03-22 隆泰申医药科技(南京)有限公司 一种化合物、其制备方法、药物组合物和应用
US12187701B2 (en) 2018-06-25 2025-01-07 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
JP2021529740A (ja) 2018-06-29 2021-11-04 キネート バイオファーマ インク． サイクリン依存性キナーゼの阻害剤
WO2020060112A1 (en) * 2018-09-17 2020-03-26 Yungjin Pharm. Co., Ltd. Novel thiazole derivatives and pharmaceutically acceptable salts thereof
WO2020202001A1 (en) 2019-04-01 2020-10-08 Aurigene Discovery Technologies Limited Substituted 5-cyclopropyl-1h-pyrazol-3-yl-amine derivatives as selective cdk12/13 inhibitors
CN110845474B (zh) * 2019-11-07 2021-01-12 四川大学 一种靶向i型prmt的化合物及其制备方法和应用
WO2021182914A1 (ko) * 2020-03-13 2021-09-16 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
CN115485274A (zh) * 2020-03-13 2022-12-16 永进药品株式会社 包含噻唑衍生物或其药学上可接受的盐的用于预防或治疗癌症的药物组合物
TWI783480B (zh) * 2020-05-27 2022-11-11 美商美國禮來大藥廠 用於抑制cdk7之化合物
WO2022084930A2 (en) * 2020-10-22 2022-04-28 Aurigene Discovery Technologies Limited Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent
KR20230159363A (ko) 2020-12-18 2023-11-21 오리진 온콜로지 리미티드 Cdk 억제제의 공결정
US20240246917A1 (en) * 2021-04-27 2024-07-25 Aurigene Oncology Limited Process for preparing a cdk inhibitor
IL309013A (en) * 2021-06-16 2024-01-01 Blueprint Medicines Corp Converted pyrimidinylpyrazoles as CDK2 inhibitors
CR20230598A (es) 2021-06-28 2024-04-25 Blueprint Medicines Corp Inhibidores de cdk2
WO2023107861A1 (en) * 2021-12-06 2023-06-15 Exelixis, Inc. Aminopyrazole derivatives as cdk7 inhibitors for use in treating in cancer
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
AU2023268862A1 (en) 2022-05-11 2024-08-15 Mayekawa Mfg. Co., Ltd. Slicing device, and method for slicing workpiece
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd
CN115093397B (zh) * 2022-06-07 2023-09-05 自贡市第三人民医院 一种用于治疗肿瘤的化合物、合成方法及应用
WO2024066984A1 (zh) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 三并环类衍生物、药物组合物以及应用
WO2024140653A1 (zh) * 2022-12-27 2024-07-04 南京圣和药业股份有限公司 选择性cdk12/13抑制剂及其应用
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57169465A (en) * 1981-04-13 1982-10-19 Showa Denko Kk Pyrazole derivative, its preparation and herbicide
EP1159264A2 (en) 1999-02-11 2001-12-05 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
EE200200065A (et) 1999-08-12 2003-04-15 Pharmacia Italia S.P.A. 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon
US7541354B2 (en) * 2000-08-10 2009-06-02 Pfizer Italia S.R.L. Bicyclo-pyrazoles
US6455559B1 (en) 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
AU2002215053A1 (en) 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
DE10148618B4 (de) * 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
US7312353B2 (en) 2003-08-21 2007-12-25 Merck Frost Canada & Co. Cathespin cysteine protease inhibitors
US8110573B2 (en) 2004-12-30 2012-02-07 Astex Therapeutics Limited Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases
JP2008526723A (ja) * 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
BRPI0606319A2 (pt) 2005-01-21 2009-06-16 Astex Therapeutics Ltd compostos farmacêuticos
GT200600457A (es) 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2
US20110269740A1 (en) * 2008-07-02 2011-11-03 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
EP2313758B1 (en) 2008-07-17 2012-02-01 Koninklijke Philips Electronics N.V. Nanopore device and a method for nucleic acid analysis
RU2505540C2 (ru) 2008-12-23 2014-01-27 Эббви Инк. Антивирусные соединения
FR2943058B1 (fr) 2009-03-11 2011-06-03 Centre Nat Rech Scient Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
EP2241619A1 (en) * 2009-04-17 2010-10-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Development of fluorescently P-loop labeled kinases for screening of inhibitors
EP2822935B1 (en) * 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US9657006B2 (en) 2013-06-13 2017-05-23 Bristol-Myers Squibb Company Macrocyclic factor VIIa inhibitors
SG11201601341QA (en) 2013-08-30 2016-03-30 Ambit Biosciences Corp Biaryl acetamide compounds and methods of use thereof
RS59140B1 (sr) 2013-10-21 2019-09-30 Merck Patent Gmbh Heteroarilna jedinjenja kao inhibitori btk i njihova upotreba
EP3129371B1 (en) 2014-04-05 2020-07-29 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
FR3025075A1 (fr) * 2014-08-28 2016-03-04 Oreal Nouveau dispositif de soin et/ou maquillage comprenant une composition d’architecture gel/gel
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
HRP20240101T1 (hr) * 2015-06-04 2024-03-29 Aurigene Oncology Limited Supstituirani heterociklil derivati kao cdk inhibitori

Also Published As

Publication number Publication date
CA2987552A1 (en) 2016-12-08
JP2018516917A (ja) 2018-06-28
HK1255239A1 (zh) 2019-08-09
IL255960B (en) 2021-10-31
CU20170154A7 (es) 2018-07-05
EA037236B1 (ru) 2021-02-25
EP3302448B1 (en) 2023-10-25
US10689347B2 (en) 2020-06-23
US20180155293A1 (en) 2018-06-07
LT3302448T (lt) 2024-02-12
IL255960A (en) 2018-01-31
PH12017502179B1 (en) 2024-07-03
DK3302448T3 (da) 2024-02-05
EA201890001A1 (ru) 2018-04-30
JP7033764B2 (ja) 2022-03-11
MX2020010484A (es) 2020-10-22
AU2023203524A1 (en) 2023-06-29
JP6750806B2 (ja) 2020-09-02
WO2016193939A1 (en) 2016-12-08
EP4342540A3 (en) 2024-05-29
JP2020196726A (ja) 2020-12-10
CN108024970B (zh) 2021-10-01
AU2016272908A1 (en) 2018-01-25
SI3302448T1 (sl) 2024-03-29
US20180362471A9 (en) 2018-12-20
FI3302448T3 (fi) 2024-01-24
AU2021212016A1 (en) 2021-08-26
HRP20240101T1 (hr) 2024-03-29
PH12017502179A1 (en) 2018-05-28
EP3302448A4 (en) 2018-11-14
US20200262793A1 (en) 2020-08-20
MY190459A (en) 2022-04-21
US20230250062A9 (en) 2023-08-10
US11174232B2 (en) 2021-11-16
AU2021212016B2 (en) 2023-03-09
CN108024970A (zh) 2018-05-11
MX2017015521A (es) 2018-11-09
CN113773257A (zh) 2021-12-10
KR20180041112A (ko) 2018-04-23
JP7482918B2 (ja) 2024-05-14
IL286428A (en) 2021-10-31
JP2022078121A (ja) 2022-05-24
EP3302448A1 (en) 2018-04-11
AU2016272908B2 (en) 2021-05-06
KR102691467B1 (ko) 2024-08-02
NZ738825A (en) 2024-09-27
EP4342540A2 (en) 2024-03-27
US20220098156A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
CU24496B1 (es) Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk
ECSP20067394A (es) Inhibidores de cinasa dependientes de ciclina
CL2017002994A1 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CY1123595T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
MX2018009158A (es) Compuestos organicos.
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
MX2019007474A (es) Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
MX2016013046A (es) Compuestos organicos.
CL2017003325A1 (es) Derivados de 3-tetrazolilo-benceno-1,2-disulfonamida como inhibidores de metalo-beta-lactamasa
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
SV2016005313A (es) Derivados de carboxamida
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
CO2017005806A2 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos
MX2018007432A (es) Compuestos de dihidroquinolinsulfonamida de alquilo.
CL2017002229A1 (es) Inhibidores de bace1.